US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Imprimis Pharmaceuticals

5.69

0.0000

Volume:- -

Turnover:- -

Market Cap:132.45M

PE:-19.55

High:5.69

Open:5.69

Low:5.69

Close:5.69

52wk High:6.50

52wk Low:1.45

Shares:23.28M

Float Shares:4.37M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.2911

EPS(LYR):-0.5984

ROE:--

ROA:--

PB:29.74

PE(LYR):-9.51

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Imprimis Pharmaceuticals

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.imprimispharma.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Imprimis Pharmaceuticals, Inc. engages in the development, production, and dispensing of proprietary compounded pharmaceutical products to physicians and patients in the United States. It owns, markets, and sells a portfolio of proprietary combination formulations in the areas of ophthalmology, otolaryngology, urology, and infectious diseases therapeutic areas. The company also provides compounded therapeutic alternatives; and non-proprietary customizable compounded drugs for humans and animals, including sterile injectable and non-sterile integrative medicine therapies for oncology, autoimmunity, chronic infectious, and endocrine and metabolic diseases. In addition, it develops formulations in the areas of wound healing and dermatology therapeutic areas. The company was formerly known as Transdel Pharmaceuticals, Inc. and changed its name to Imprimis Pharmaceuticals, Inc. in February 2012. Imprimis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in San Diego, California.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IMMY/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMMY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMMY\",,,,,undefined,":{"symbol":"IMMY","market":"US","secType":"STK","nameCN":"Imprimis Pharmaceuticals","latestPrice":5.69,"timestamp":1546462800000,"preClose":5.69,"halted":8,"volume":0,"delay":0,"changeRate":0,"floatShares":4370000,"shares":23277975,"eps":-0.29108,"marketStatus":"Closed","change":0,"latestTime":"01-02 16:00:00 EST","open":5.69,"high":5.69,"low":5.69,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.29108,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771318800000},"marketStatusCode":5,"symbolChange":{"newSymbol":"HROW","executeDate":"2019-01-02"},"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":5.69,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMMY\",,,,,undefined,":{"symbol":"IMMY","floatShares":4370000,"roa":"--","roe":"--","lyrEps":-0.59842,"shares":23277975,"dividePrice":0,"high":5.69,"amplitude":0,"preClose":5.69,"low":5.69,"week52Low":1.451,"pbRate":"29.74","week52High":6.5,"institutionHeld":0,"latestPrice":5.69,"eps":-0.29108,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.29108,"open":5.69},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMMY\",params:#limit:5,,,undefined,":[{"date":"2019-01-02","symbol":"IMMY","newSymbol":"HROW","type":"symbolChange","dateTimestamp":1546405200000},{"market":"US","date":"2018-11-13","symbol":"IMMY","fiscalQuarterEnding":"2018/09","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1542085200000,"reportTimeType":"","actualEps":-0.12},{"market":"US","date":"2018-08-06","symbol":"IMMY","fiscalQuarterEnding":"2018/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1533528000000,"reportTimeType":"","actualEps":0.12},{"market":"US","date":"2018-05-15","symbol":"IMMY","fiscalQuarterEnding":"2018/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1526356800000,"reportTimeType":"","actualEps":-0.17},{"market":"US","date":"2018-03-08","symbol":"IMMY","fiscalQuarterEnding":"2017/12","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1520485200000,"reportTimeType":"","actualEps":-0.13}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMMY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IMMY\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.imprimispharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":-0.018},{"period":"3month","weight":0.0139},{"period":"6month","weight":0.0588},{"period":"1year","weight":0.1291},{"period":"ytd","weight":-0.001}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Imprimis Pharmaceuticals, Inc. engages in the development, production, and dispensing of proprietary compounded pharmaceutical products to physicians and patients in the United States. It owns, markets, and sells a portfolio of proprietary combination formulations in the areas of ophthalmology, otolaryngology, urology, and infectious diseases therapeutic areas. The company also provides compounded therapeutic alternatives; and non-proprietary customizable compounded drugs for humans and animals, including sterile injectable and non-sterile integrative medicine therapies for oncology, autoimmunity, chronic infectious, and endocrine and metabolic diseases. In addition, it develops formulations in the areas of wound healing and dermatology therapeutic areas. The company was formerly known as Transdel Pharmaceuticals, Inc. and changed its name to Imprimis Pharmaceuticals, Inc. in February 2012. Imprimis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in San Diego, California.","exchange":"NASDAQ","name":"Imprimis Pharmaceuticals","nameEN":"Imprimis Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"IMMY\",market:\"US\",,,undefined,":null}}